Clinical data | |
---|---|
Trade names | Vistogard, Xuriden |
Other names | vistonuridine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616020 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Pyrimidine catabolic pathway |
Onset of action | Tmax = 2–3 hours |
Elimination half-life | 2–2.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.021.710 |
Chemical and physical data | |
Formula | C15H18N2O9 |
Molar mass | 370.314 g·mol−1 |
3D model (JSmol) | |
| |
|
Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11]